Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

NCT05559541 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

33

Enrollment

INDUSTRY

Sponsor class

Stopped Development strategy adjustment

Conditions

Solid Tumor, Adult

Interventions

DRUG: AK119
DRUG: AK104

Sponsor

Akeso